Viking Therapeutics has initiated a ~280-patient phase 2a study of oral VK2735, with management guiding for a result in H2'25. Previous trials of VK2735 have enrolled ahead of schedule ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7 ...

Viking Therapeutics has reported positive data from its Phase I multiple ascending dose (MAD) clinical trial of VK2735, an oral tablet under investigation for the treatment of metabolic disorders ...

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.

Many investors may have been hoping that another, larger healthcare company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening. And with a ...

Viking Therapeutics is looking to carve out a niche thanks to VK2735, a potential anti-obesity therapy that aced phase 2 studies last year. True, this mid-cap biotech still looks risky.

Viking is developing VK2735 in injectable format and in an oral version. The former is set to enter phase 3 studies in the second quarter and the latter is involved in a phase 2 study right now.

The data released by Viking showed that adults taking the highest dosage of the oral VK2735 tablet lost an average of 8.2% of their body weight in just four weeks, or 6.8% more than those that ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment ...